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Abstract
Background: Improving the outcomes of HIV/AIDS treatment programs in resource-limited settings requires successful
linkage of patients testing positive for HIV to pre–antiretroviral therapy (ART) care and retention in pre-ART care until ART
initiation. We conducted a systematic review of pre-ART retention in care in Africa.
Methods and Findings: We searched PubMed, ISI Web of Knowledge, conference abstracts, and reference lists for reports
on the proportion of adult patients retained between any two points between testing positive for HIV and initiating ART in
sub-Saharan African HIV/AIDS care programs. Results were categorized as Stage 1 (from HIV testing to receipt of CD4 count
results or clinical staging), Stage 2 (from staging to ART eligibility), or Stage 3 (from ART eligibility to ART initiation). Medians
(ranges) were reported for the proportions of patients retained in each stage. We identified 28 eligible studies. The median
proportion retained in Stage 1 was 59% (35%–88%); Stage 2, 46% (31%–95%); and Stage 3, 68% (14%–84%). Most studies
reported on only one stage; none followed a cohort of patients through all three stages. Enrollment criteria, terminology,
end points, follow-up, and outcomes varied widely and were often poorly defined, making aggregation of results difficult.
Synthesis of findings from multiple studies suggests that fewer than one-third of patients testing positive for HIV and not
yet eligible for ART when diagnosed are retained continuously in care, though this estimate should be regarded with
caution because of review limitations.
Conclusions: Studies of retention in pre-ART care report substantial loss of patients at every step, starting with patients who
do not return for their initial CD4 count results and ending with those who do not initiate ART despite eligibility. Better
health information systems that allow patients to be tracked between service delivery points are needed to properly
evaluate pre-ART loss to care, and researchers should attempt to standardize the terminology, definitions, and time periods
reported.
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The remarkable expansion of access to antiretroviral therapy
(ART) for HIV/AIDS in resource-constrained countries has given
nearly four million HIV-positive adults in sub-Saharan Africa the
opportunity to achieve what for many may be nearly normal life
expectancies [1]. Others, however, do not make it past their first
year on treatment. The rate of early mortality and loss to follow-
up, which itself portends mortality for many, averages 23% across
the region [2]. For patients initiating ART late, with very low CD4
counts, the odds of success are even lower: in a pooled analysis of
data from multiple resource-limited countries, patients with
starting CD4 counts below 25 cells/mm
3 faced a more than 3-
fold increased risk of death compared to those with starting CD4
counts above 50 cells/mm
3 [3]. Those who survive suffer more
morbidity and utilize more medical care resources than would
otherwise have been necessary [4].
Earlier initiation of ART requires earlier diagnosis and regular
monitoring until treatment eligibility. Despite large-scale HIV
testing campaigns to hasten diagnosis [5] and the raising of CD4
count thresholds to allow earlier ART eligibility [1], late
presentation for AIDS treatment remains the norm. Median
baseline CD4 counts have increased only modestly in the years
since treatment became available [6,7], and most programs still
report medians well below even the very low threshold of 200
cells/mm
3 previously allowed by most treatment guidelines [2].
The persistence of low starting CD4 counts points to a problem
that has just begun to be recognized in the research literature:
poor pre-ART retention in care, or the failure to link patients from
HIV testing to HIV care and retain them in care until they are
eligible for ART. Without effective retention in pre-ART care,
beginning with HIV testing and continuing until the first
antiretrovirals are dispensed, even patients who have long been
aware of their HIV status will access care only when seriously ill,
which is often well after treatment eligibility.
A prerequisite to developing interventions to retain patients in
care between testing and treatment is an understanding of where
and when they are being lost. Research on retention in pre-ART
care is challenging, as it requires long periods of follow-up and
consistent information systems that allow individuals to be tracked
as they move in and out of care at multiple facilities. As a result,
only a handful of quantitative studies reporting on rates of pre-
ART linkage and loss have been published. In this paper, we
review those studies and summarize what is known about this issue
in sub-Saharan Africa. Our objective is to determine whether
existing data allow us to estimate what proportion of adult patients
who test positive for HIV are staged, enroll, and remain in pre-
ART care until ART-eligible, and initiate ART as soon as eligible.
Figure 1. Stages of pre-ART care.
doi:10.1371/journal.pmed.1001056.g001
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Ethics Statement
An ethics statement was not required for this work.
Search Strategy
We conducted a systematic literature review of patient retention
between HIV testing and ART initiation in sub-Saharan Africa.
Followinga detailed search protocol and standard systematic review
procedures (Texts S1 and S2), we searched the published literature
and major conference abstract archives for reports containing
primary, patient- or facility-level data from routine health-care
delivery settings on the proportion of patients retained in care
between HIV testing and ART initiation and/or rates of linkage
between any two intermediate points between testing and ART. We
excluded patients who were in care solely for the purpose of
Figure 2. Flow chart of literature search on pre-ART retention in care. Adherence conference, 5th International Conference on HIV
Treatment Adherence; CROI, Conference on Retroviruses and Opportunistic Infections; IAS, International AIDS Society; Implementers conference, HIV
Implementers Meetings.
doi:10.1371/journal.pmed.1001056.g002
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PLoS Medicine | www.plosmedicine.org 3 July 2011 | Volume 8 | Issue 7 | e1001056Table 1. Studies included in this review of retention in pre-ART HIV care in sub-Saharan Africa.
Study Code Year Location Sample (N) Dates Design
Ethiopia 1 [16] 2010 Ethiopia: national sample of
public sector sites
HIV+ patients referred for care
(1,314)
2005–2008 Evaluation of aggregate site-
level reports
Ethiopia 2 [17] 2009 Ethiopia: 33 public sector facilities HIV+ patients referred for care
(1,102)
Jan–Dec 2008 Evaluation of improved referral
procedures through collection
of referral slips brought to
referral clinic by patients after
testing
Ethiopia 3 [18] 2010 Ethiopia: Arba Minch Hospital HIV+ patients presenting at HIV
clinic (2,191)
Jan 2003–31 Dec
2008
Retrospective cohort
Kenya 1 [19] 2007 Kenya: Migori District Hospital,
Nyanza Province
ART-eligible patients from PMTCT
program (159)
Apr 2004–Sep 2005 Retrospective cohort; limited to
PMTCT participants and
partners
Kenya 2 [20] 2011 Kenya: multiple facilities,
Nyanza Province
HIV+ patients accepting
home-based testing and
follow-up interview (737)
Feb 2008–Jul 2009 Household survey of
participants in home-based HIV
testing study; self-reported
data
Kenya 3 [14] 2011 Kenya: Coptic Hope Center
for Infectious Diseases, Nairobi
ART-ineligible patients enrolled
in pre-ART care program with a
baseline CD4 count (610)
2005–2007 Retrospective cohort
Malawi 1 [21] 2010 Malawi: Martin Preuss Centre,
Bwaila District Hospital, Lilongwe
ART-eligible pregnant women
referred from PMTCT site to
ART site (742)
Dec 2006–Jan 2010 Retrospective cohort
Malawi 2 [22] 2010 Malawi: Thyolo District Hospital All newly registered care patients
in WHO stages 1/2 not on ART
and enrolled .1 mo before
data censoring (1,428)
1 Jun 2008–10 Feb
2009
Retrospective cohort
Malawi 3 [23] 2006 Malawi: Thyolo District Hospital HIV+ TB patients who completed
first 8 wk of TB treatment and
became eligible for ART (742)
Feb 2003–Jul 2004 Retrospective cohort; limited to
TB patients
Mozambique 1 [24] 2009 Mozambique: two urban HIV
care networks
HIV+ patients (6,999) 1 Jul 2004–30 Jun
2005
Facility-level analysis of
numbers completing each step
SA 1 [25] 2009 South Africa: two clinics, Cape
Town township
HIV+ patients (375); ART-eligible
patients (75)
2006
a Retrospective cohort; excluded
pregnant women
SA 2 [26]
b 2009 South Africa: McCord
Hospital, Durban
ART-eligible adults who stated
intention to start ART at site and
were assessed as ‘‘psychosocially
ready’’ for treatment (501)
Jul–Dec 2006
c Retrospective cohort
SA 3 [27]
b 2010 South Africa: McCord and St.
Mary’s Hospitals, Durban
HIV+ patients (1,474) Nov 2006–Jun 2009 Prospective cohort
SA 4 [28] 2010 South Africa: 36 facilities,
Free State Province
Patients enrolled in care with
CD4 count reported (33,122)
May 2004–Dec 2008 Retrospective cohort
SA 5 [29] 2008 South Africa: Hannan
Crusaid Treatment Centre, Gugulethu
ART-eligible patients (2,131) 1 Sep 2002–30 Sep
2007
Retrospective cohort; limited to
female patients
SA 6 [30] 2010 South Africa: Cape Town
township public clinic
HIV+ patients (988) Jan 2004–Mar 2009 Retrospective cohort
SA 7 [31] 2010 South Africa: Themba Lethu Clinic,
Helen Joseph Hospital, Johannesburg
HIV+ patients (416) Jan 2008–Feb 2009 Retrospective cohort
SA 8 [32] 2010 South Africa: Themba Lethu Clinic,
Helen Joseph Hospital, Johannesburg
Patients enrolled in pre-ART
care program (356)
Jan 2007–Feb 2008 Retrospective cohort
SA 9 [33] 2006 South Africa: Gugulethu Community
Health Centre, Western Cape Province
ART-eligible patients enrolled
at ART clinic (1,235)
Sep 2002–Aug 2005 Retrospective cohort
SA 10 [34] 2010 South Africa: Hlabisa Care and Treatment
Program, KwaZulu Natal Province
HIV+ patients not eligible
for ART (4,223)
1 Jan 2007–30 Jan
2009
Retrospective cohort
SA 11 [35]
b 2010 South Africa: McCord and St. Mary’s
hospitals, Durban
HIV+ patients (454) Nov 2006–May 2007 Prospective cohort
SA 12 [36] 2010 South Africa: Gauteng Province HIV+ patients who enrolled
in trial (199)
Not reported Preliminary data for cohort
enrolled in trial; self-reported
data; limited to female IDUs
and CSWs
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in pediatric care, modeled estimates without primary data,
qualitative studies, and clinical trials that did not take place under
routine care conditions. We included reports of trials of procedural
changes within facilities. Where multiple reports described the same
data, the one reporting the most complete follow-up or with the
clearest definitions of outcomes was used. We did not place a
language restriction on the papers included in our search but did
limit the search to English-language indices.
We searched PubMed and the ISI Web of Knowledge through
January 5, 2011, with the combined terms ‘‘Africa’’ and ‘‘HIV’’ plus
‘‘retention,’’ ‘‘linkage,’’ or ‘‘pre-ART.’’ We searched the African
Indicus Medicus through April 1, 2011, using the same terms. We also
searched abstracts from the conferences of the International AIDS
Society from 2008 to 2010 and from the Conference on Retroviruses
and Opportunistic Infections from 1997 to 2011, and scanned the titles
of abstracts presented at the HIV Implementers Meetings in 2008 and
2009 and the 5th International Conference on HIV Treatment
Adherence (2010). Finally, we reviewed the reference lists of all papers
found through the PubMed and ISI Web of Knowledge searches.
S. R. assessed the eligibility of all abstracts and journal articles
that met our initial criteria, and M. P. F. confirmed eligibility.
Using a standard data extraction form, both authors extracted and
reviewed the relevant data, including study site, sample size and
inclusion criteria, dates of data collection, study design and
outcomes, and quantitative results.
Data Analysis
We anticipated that wide variation in definitions, outcomes, and
specific components of pre-ART care evaluated in the studies
would prevent aggregate statistical analysis of findings beyond a
basic descriptive level. We therefore began by describing each
study, identifying the start and end points of the data presented,
and specifying the proportions of patients retained or linked. We
defined ‘‘loss to care’’ as failing to reach the next step in the care
sequence for any reason (death or discontinuation), but we also
accepted each study’s own criteria for determining which patients
died or discontinued care. Transfers were rarely distinguished
from losses in the published studies. Where possible, we used the
reported data to calculate a 95% confidence interval for the
proportion of patients retained or linked. Next, we grouped the
findings into stages within the testing-to-ART-initiation sequence,
as described below, and illustrated the results using forest plots.
Finally, for each stage we estimated the median proportion of
patients completing the stage and reported the median and range.
Classification of Results
Preliminary review of the literature suggested that the sequence of
events that starts with testing positive for HIV and ends with initiating
ART can usefully be grouped into three stages, as illustrated in
Figure 1. For analysis, we categorized each study by stage, allowing
some studies to be included in more than one stage as appropriate.
Stage 1, in which the patient is staged for referral to either pre-
ART care or ART, starts immediately after a patient tests positive for
HIV infection. Depending on the technology availableand the testing
setting, Stage 1 typically requires the patient to make one or two
additional visits to a clinic. A blood sample for a CD4 count can be
given during the same visit as the HIV test if the test is conducted at a
clinic; if the test is done at a stand-alone testing site, the patient is
typically referred elsewhere to provide a blood sample. Once the
sample has been taken, patients are asked to return 2 d to 2 wk later
toreceivetheirresults,withthetimeintervaldependentonlaboratory
processing capacity and location. Completion of Stage 1 requires that
patients receive their CD4 count results (or clinical staging outcome)
and be referred onward for pre-ART care or ART.
Stage 2 lasts from enrollment in pre-ART care until eligibility for
ART. Stage 2 pertains only to patients who complete Stage 1 prior
to ART eligibility, as those already eligible for ART at staging will
be referred directly to Stage 3. The steps included in Stage 2 are
generally poorly defined in the literature and vary widely from
program to program. In some programs ‘‘enrollment in care’’
happens automatically when a patient presents at a site, regardless
of patient intention, while in others it requires active patient
participation. Patients may be considered enrolled in care prior to
staging or only after having been found not-yet-eligible for ART. At
a minimum, retention in pre-ART care requires regular clinic visits
Study Code Year Location Sample (N) Dates Design
SA 13 [37] 2010 South Africa: Esselen St. Clinic,
Hillbrow, Johannesburg
HIV+ patients (224) Not reported Trial of immediate or 1-wk CD4
results; source reported only on
1-wk outcomes
SA 14 [38] 2011 South Africa: mobile testing units, Cape
Metropolitan Region, Western Cape
Province
HIV+ patients (192) Aug 2008–Dec 2009 Phone follow-up of patients
who tested positive at mobile
testing units, with confirmation
by record review
Tanzania 1 [39] 2009 Tanzania: VCT site and clinic in Kisesa WardHIV+ patients (349) Mar 2005–Feb 2008 Evaluation of referral forms
Uganda 1 [40] 2009 Uganda: AIDS Support Clinic, Jinja ART-eligible patients (2,483) Sep 2004–Dec 2006
c Retrospective cohort
Uganda 2 [41] 2010 Uganda: Mulago Hospital, Kampala HIV+ in-patients (208) Mar 2004–Mar 2005
c Trial of offering HIV test during
inpatient stay or referral to
outpatient HIV test after
discharge; limited to previously
hospitalized patients
Uganda 3 [42] 2011 Uganda: Immune Suppression Syndrome
(ISS) Clinic, Mbarara
ART-eligible patients (2,639) Oct 2007–Jan 2011 Retrospective cohort
aUsed data for 2006 only because data provided for earlier years were incomplete.
bSamples in SA 2, SA 3, and SA 11 may overlap.
cFollow-up may have continued beyond this date; source ambiguous.
CSW, commercial sex worker; IDU, intravenous drug user; PMTCT, prevention of mother-to-child transmission; TB, tuberculosis; VCT, voluntary counseling and testing.
doi:10.1371/journal.pmed.1001056.t001
Table 1. Cont.
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thesevisitsvarieswidely:patientswithveryhighCD4countsmaybe
asked to return as infrequently as once a year, while those
approaching treatment eligibility may be monitored on a monthly
or quarterly basis. Similarly, some programs routinely dispense
cotrimoxazole, isoniazid, vitamins, and/or foodsupplements to pre-
ART patients, while others simply assess condition. For practical
purposes, completion of Stage 2 requires that ART eligibility be
determined prior to the patient’s CD4 count falling substantially
below the eligibility threshold or the patient becoming severely ill.
Finally, Stage 3 encompasses the steps between determination of
ART eligibility and ART initiation. Programs in sub-Saharan
Africa typically require two or more ‘‘treatment readiness’’ visits
during this stage, and the full course of treatment education and
adherence training can last for up to 8 wk. Completion of Stage 3
requires that the patient be dispensed a first dose of antiretrovirals.
Results
We identified 668 full-length journal articles and 1,145 abstracts
potentially relevant to our review. As shown in the search
flowchart in Figure 2, after excluding duplicates and studies that
did not meet the geographic, population, content, or design
criteria of our review, 20 full-length articles and eight abstracts
were eligible for the review. Most (23/28) were published or
presented in 2009 or later. Seven countries are represented, but
half the studies (14/28) were conducted in just one, South Africa.
Most (18/28) were designed as retrospective cohorts using
routinely collected patient-level data; the remaining were program
evaluations, trials of procedural changes, and a prospective cohort.
The studies are described in Table 1, which also contains the study
codes we will use to refer to individual studies throughout this
paper. Of the 28 studies included, 20 reported information
relevant to only one stage in the testing-to-treatment sequence, six
addressed two stages, and two addressed to all three stages. We
thus had a total of 38 stage-specific observations.
Stage 1: Testing to Staging
Ten studies reported rates of staging after a positive HIV test
(Table 2 and Figure 3). Time intervals for evaluating results varied
widely, from 1 wk to 6 mo. In general, between one-third and
two-thirds of patients testing positive for HIV provided samples for
Table 2. Reported rates of retention or linkage in Stage 1 (HIV testing to staging).
Study Code Outcome Assessed N
Number Achieving
Outcome
Percent (95% CI)
Achieving Outcome Comments
Provided sample for CD4 count
SA 1 #6 mo of HIV test 375 232 62% (57%–67%) Source does not specify whether
patients returned for results
SA 6 #6 mo of HIV test 988 621 63% (60%–66%) Source states that authors do not
know whether patients returned for
results; mean for those providing
sample in .6m o=4 9 0d
.6 mo of HIV test 988 112 11% (9%–13%)
Never 988 255 26% (23%–29%)
Returned for CD4 count results after providing sample
Malawi 2 #1 mo of registering for care 1,428 784 55% (52%–57%)
SA 7 #12 wk of HIV test 352 122 35% (30%–40%)
SA 13 #1 wk of providing sample 224 106 47% (41%–54%)
SA 14 Ever 192 149 78% (72%–84%) No maximum time limit indicated
Uganda 1 Ever 2,483 2,182 88% (87%–89%) All patients enrolled in study were
ART-eligible at time of providing CD4
count sample; no maximum time limit
indicated
Of above total, returned #21 d 2,483 1,637 66% (64%–68%)
Provided sample and returned for CD4 count results
Mozambique 1 #60 d of HIV test 6,999 3,046 44% (42%–45%)
Of above total, enrolled in care
#30 d of HIV test
7,005 3,950 56% (55%–58%)
Of above total, returned for CD4
results #30 d of enrollment
3,950 3,046 77% (76%–78%)
SA 3 #90 d of HIV test 1,474 1,012 69% (66%–71%) Source is ambiguous but appears to
refer to receipt of CD4 results, rather
than solely provision of sample
SA 11 Ever 454 212 47% (42%–51%) No maximum time limit is indicated
for returning for results
Of above total, provided sample
for CD4 testing #8 wk of HIV test
454 248 55% (50%–59%)
Of above total, ever returned for
results
248 212 85% (81%–89%) No maximum time limit is indicated
for returning for results
doi:10.1371/journal.pmed.1001056.t002
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test. For all the studies in Table 2, the median proportion of
patients completing one or both of the steps in Stage 1 was 59%
(range 35%–88%).
Stage 2: Staging to ART Eligibility
Fourteen studies reporting on retention in pre-ART care
between staging and ART eligibility (Stage 2) are shown in
Table 3 and Figure 4. The upper rows of Table 3, which report on
enrollment in pre-ART care after a positive HIV test, clearly
overlap with some of the studies classified as Stage 1 and presented
in Table 2, but we placed them in Stage 2 because they focus on
pre-ART care rather than staging. Similarly, many of the studies
in the lower rows of Table 3, which report on retention in pre-
ART care after enrollment, use ART initiation as an end point,
overlapping with Stage 3.
The first eight studies in Table 3 reported the proportion of
patients who enrolled in an HIV care program after testing. Time
intervals allowed for completing this step varied from ‘‘immedi-
ately’’ after the HIV test to a year after staging, and ‘‘enrollment in
care’’ was itself not consistently defined. Across the studies, the
median proportion of patients enrolling in care after a positive
HIV test was 44% (range 31%–68%).
The last six studies in Table 3 reported on retention in
ART care after enrollment. Four provided results up to the
date of data censoring, rather than up to a clinically
meaningful end point within the stage or to a consistent
duration of follow-up of all patients in the cohort. In most of
these cases, the outcome assessed was the proportion of
patients who either initiated ART or remained in pre-ART
care at the censoring date. In these studies, a median of 55%
(range 42%–95%) of patients reached the study end point
(repeat CD4 count, ART initiation, 12 months of follow-up,
or data censoring), while the rest died or were lost to follow-
up before the end point.
Stage 3: ART Eligibility to ART Initiation
The 14 studies reporting on Stage 3 are summarized in Table 4
and illustrated in Figure 5. Stage 3 has the most consistent and
precise start and end points: from a clearly defined threshold,
treatment eligibility, to a definite event, ART initiation. Across all
the studies in Table 4, a median of 68% (range 14%–84%) of
Figure 3. Forest plot of the ten studies reporting on the proportion of patients completing Stage 1 or steps within Stage 1. Bars
indicate 95% confidence intervals. Studies shown in the plot report to differing end points; refer to Table 2 for details.
doi:10.1371/journal.pmed.1001056.g003
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study periods of observation. As with Stage 1 and Stage 2, the time
intervals allowed for the completion of Stage 3 varied widely and
were in some cases unclear.
Multi-Stage Follow-Up
Eight studies contained data pertaining to more than one stage
between testing and treatment initiation. These studies are listed
multiple times in Tables 2–4 above, but the patient samples assessed
at each stage did not remain consistent between stages in all of the
studies. In Table 5, we provide multi-stage results for the relevant
studies. Even the most comprehensive studies, such as Malawi 2 and
SA 6, did not report outcomes to the end of a stage for all patients
enrolled. Four of the seven studies that started with Stage 1 followed
through to Stage 3 only those patients who were already eligible for
ART in Stage 1—no further follow-up was reported of patients who
were not yet eligible for ART and should have progressed to Stage 2.
Discussion
During the early years of HIV/AIDS treatment scale up in sub-
Saharan Africa, attention was focused on initiating eligible patients
on ART and, more recently, on long-term retention in care of
those patients on treatment. Growing awareness of the negative
consequences of late presentation for treatment, combined with
new enthusiasm for test-and-treat strategies, is now leading to
renewed interest in the pre-ART period, which is after HIV
diagnosis but before treatment.
Our analysis of 24 studies documenting rates of retention of
patients from testing positive for HIV infection to initiating ART
suggests that patient management during this period poses serious
challenges. Most studies reported a substantial reduction in patient
numbers at every step of the process. This reduction in patient
numbersisclearlyillustrated inFigure6,whichsummarizesfindings
from all the reports. Studies are few, however, and offering a
Table 3. Reported rates of retention or linkage in Stage 2 (staging to ART eligibility).
Study Code Outcome Assessed N
Number Achieving
Outcome
Percent (95% CI)
Achieving Outcome Comments
HIV test to enrollment in care
Ethiopia 1 ‘‘Immediate’’ linkage to HIV
care after HIV test
1,314 623 47% (45%–50%) ‘‘Linked to care’’ and
‘‘immediately’’ not defined in
report
Ethiopia 2 Visited referral site (HIV clinic)
after HIV test
1,102 474 43% (40%–46%) Of 474 visiting referral site, 84%
visited #8 wk of HIV test
Kenya 2 Self-reported attendance at HIV
care services 2–4 mo after HIV test
737 312 42% (39%–46%)
SA 8 Attended first pre-ART medical
appointment #1 y of staging
356 112 31% (27%–36%)
SA 12 Visited referral site (HIV clinic)
after HIV test
199 92 46% (39%–53%) Self-reported data; time allowed to
reach end point not stated
SA 14 Self-reported access of HIV care 135 49 36% (28%–44%) Of those not linked, 1% died and
41% not reached by phone. Self-
reported data confirmed by record
review. Time limit for accessing
care not clear
Tanzania 1 Registered at HIV clinic #6m o
of referral from testing
349 237 68% (63%–73%)
Uganda 2 Self-reported attendance at
HIV clinic #6 mo of HIV test
203 92 45% (39%–52%) Self-reported data; denominator
includes 55 patients who died
#3 mo of HIV test
Retention in pre-ART care after enrollment
Ethiopia 3 Percent initiating care or still
in care at date of data censoring
(follow-up duration unknown)
2,191 1,540 70% (68%–72%) Of 651 not retained, 102 died and
549 lost to follow-up; proportion
retained includes 34 who
transferred out of program
Kenya 3 ,30 d late for most recent pre-ART
appointment or drug pickup 12
mo after enrollment in pre-ART care
610 384 63% (59%–67%) Data are for period before
distribution of cotrimoxazole to
pre-ART patients
Malawi 2 Percent initiating care or still in care
at date of data censoring
(7 mo of follow-up)
852 808 95% (93%–96%) 45% of original sample did not
return for CD4 count results and
thus did not reach Stage 2; see
Table 2
SA 10 Repeat CD4 count #13 mo of
first CD4 count
4,223 1,896 45% (43%–46%)
SA 4 Percent initiating care or still in care at
date of data censoring (up to 3.5 y of
follow-up)
11,039 4,672 42% (41%–43%) Of 6,367 not retained, 1,337 died
and 5,030 lost to follow-up
SA 6 Repeat CD4 count by date of data
censoring (up to 5 y of follow-up)
191 46% (41%–50%)
doi:10.1371/journal.pmed.1001056.t003
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who test positive for HIV are staged, enroll and remain in pre-ART
care until ART eligibility, and initiate ART—is not possible with
the data available. Only a handful of countries are represented, and
most by no more than one or two studies. No study provides all the
information neededto answerthis question,even fora singlesetting,
and combining results from multiple studies appears ill-advised. To
examine the implications of doing this, we multiplied the median
proportions of patients achieving the study end point in each stage
(Stage 1, 59%; Stage 2, 46%; Stage 3, 68%), and found that the
information available suggests that only about 18% of patients who
are not yet eligible for ART when they are diagnosed with HIV
remain continuously in care until ART eligibility. When we instead
multiplied all combinations of estimates from each of the three
stages, we estimated a median completion of all three stages of 17%,
with an interval from the 10th to the 90th percentile of 7%–32%.
If we make one optimistic assumption, we can use the data in
the most complete study in our review—SA 6, which tracked
patients from provision of a sample for a CD4 count to either
ART initiation or a repeat CD4 count—to answer the question for
one setting. In SA 6, 988 patients were enrolled after testing
positive for HIV. By the end of the study, 141 had initiated ART,
and 189 had returned for at least one repeat CD4 count. If we
optimistically assume all 189 in the latter group remained in pre-
ART care until ART initiation, then the overall retention rate for
this population was 33%, better than what we estimated by
multiplying the medians but still very low. While it is difficult to
believe that only a sixth to a third of patients remain continuously
in care, the evidence does not allow us to make a more definitive
estimate.
There appear to be several main reasons for the poor
performance of pre-ART care in retaining patients. Most patients
during this stage are asymptomatic and may not perceive
themselves as requiring medical care. Since very little therapeutic
care is offered during the pre-ART period, patients must take it on
faith that making the effort to come to the clinic for monitoring is
worth the costs of doing so. Current approaches to providing care
often require multiple clinic visits, for example, to first provide a
blood sample for a CD4 count and then return a week later to
receive the results. Choosing to ‘‘wait and see what happens’’ may
well be a preferred strategy for patients who lack resources for
transport, risk losing employment by taking time off work, or fear
Figure 4. Forest plot of the 14 studies reporting on the proportion of patients completing Stage 2 or steps within Stage 2. Bars
indicate 95% confidence intervals. Studies shown in the plot report to differing end points; refer to Table 3 for details.
doi:10.1371/journal.pmed.1001056.g004
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who already have very low CD4 counts at their first presentation for
HIVcare,donot completeStage3becausetheydiebeforedoingso.
A number of the papers we reviewed stratified results by CD4 count
range and/or identified other factors associated with pre-ART
attrition, and a review of these findings would be valuable.
In interpreting the results summarized above, it should also be
kept in mind that there is far more mobility among HIV patients
than had been anticipated [8]. Loss to follow-up at any one site
may or may not indicate that a patient has dropped out of care
permanently. Some patients may have returned to the same site
after the data for the study were censored or the study’s definition
of loss to care reached. Many patients may have simply
transferred, usually informally, from one site to another. Difficult
as this problem is for managing ART patients, it is even worse
during the pre-ART period, because patients are expected to visit
the clinic less frequently, and more clinics are able to provide pre-
ART services than are accredited to offer ART. For individual
patients, dropping out of pre-ART care is less likely to represent a
death sentence than is loss to follow-up after initiating treatment.
Patients lost to pre-ART care mainly risk becoming late presenters
to treatment, not dying. It is reasonable to assume that many, if
not most, patients who drop out of pre-ART care will return to the
health-care system at some later date, most likely once they
become seriously ill. Without an effective health information
system that allows patients to be tracked from site to site and over
time, as they come and go from care, it is nearly impossible to
assess the extent to which patient mobility mitigates the observed
loss to care rates.
While pre-ART loss to care may not pose as immediate a
mortality threat as loss of patients who already have clinical
AIDS, it is still a major impediment to improving the outcomes of
HIV care and treatment overall, is itself a contributor to the high
mortality observed during the first year on ART, and wastes
scarce health system resources. What can be done to begin to
address this problem? We have heard of several operational
solutions currently being evaluated, involving adjustments in
referral procedures, improvements in the information provided to
patients, reminders conveyed by text message or phone, or an
increase in the number of steps that can be completed in a single
visit. We have seen few rigorous evaluations of interventions,
however. One exception, which is currently being evaluated in
several settings, is the use of point-of-care CD4 count technology
to reduce the number of visits to the clinic in Stage 1 [9–13].
Another promising strategy is to dispense prophylaxis for
opportunistic infections, such as cotrimoxazole and isoniazid,
more actively to pre-ART patients; a study in Kenya reported
that retention of pre-ART patients 12 mo after enrollment
improved from 63% to 84% after provision of cotrimoxazole was
introduced [14].
Table 4. Reported rates of retention or linkage in Stage 3 (ART eligibility to ART initiation).
Study Code
Time Interval Allowed for ART
Initiation N Number Initiating ART
Percent (95% CI)
Initiating ART Comments
Kenya 1 By date of data censoring (no time
limit indicated)
159 124 78% (71%–84%)
Malawi 1 Not stated 742 314 42% (39%–46%) Limited to ART-eligible
pregnant women
Malawi 2 By date of data censoring 681 437 64% (61%–68%)
Malawi 3 $8 wk after starting TB
treatment (no time limit indicated)
742 101 14% (11%–16%) Limited to TB patients;
ART eligibility based on TB
diagnosis
Mozambique 1 #90 d of eligibility 1,506 471 31% (29%–34%)
SA 1 #6 mo of eligibility 75 51 68% (57%–78%)
SA 2 #3 mo of last required
pre-ART visit
501 416 83% (80%–86%) Includes eight patients still
preparing to start ART; of
those not initiating ART,
82 lost to follow-up and
three died
SA 3 By date of data censoring
(median follow-up of 12 mo)
538 210 39% (35%–43%)
SA 4 By date of data censoring
(up to 3.5 y of follow-up)
22,083 14,179 64% (64%–65%) Includes 1,216 patients
still in pre-ART care at date
of data censoring
SA 5 2,131 1,758 82% (81%–84%) Weighted average of
results for pregnant and
non-pregnant patients;
time interval not stated
SA 6 #6 mo of HIV test if ART eligibility
confirmed #6 mo of HIV test
219 146 67% (60%–73%)
SA 9 By date of data censoring
(3 y of follow-up)
1,235 1,034 84% (82%–86%)
Uganda 1 2,483 1,846 74% (73%–76%) Time interval not stated
Uganda 3 #1 y of enrollment in care
if ART-eligible at enrollment
2,639 2,085 79% (77%–81%)
TB, tuberculosis.
doi:10.1371/journal.pmed.1001056.t004
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A discussion of interventions is beyond the scope of this paper
but would warrant further investigation. What we do wish to
discuss are two issues that arise directly from this review. First, the
review made painfully clear the need for standardization of
terminology, definitions, time intervals, and end points that
should be reported for the pre-ART period. The three-stage
structure presented here may provide a framework for classifying
results, but it is no more than a starting point. We have three
recommendations for how researchers might begin to address this
issue. First, proposals for clearly defined outcomes within each
stage, and standard terminology to describe those outcomes and
to label the phenomenon of pre-ART loss to care overall, would
be helpful. Suggestions from researchers involved in work in this
area, and thus familiar with data availability and limitations,
would be welcome. Second, more effort should be made to report
quantitative data comprehensively. We were forced to exclude
from our review one paper and several conference abstracts that
indicated that the authors likely had the data required to make
quantitative estimates of retention in pre-ART care but did not
report them or reported them incompletely. Having a standard
set of indicators and outcomes, as suggested above, would also
help to solve this second problem. And third, using data
censoring as an end point should be avoided when possible, in
favor of a clinically meaningful end point or a fixed duration of
follow-up.
The second issue highlighted by this review is the absence of
health information systems that allow patients to be tracked
between service delivery points. We did not find a single study
that was able to follow a cohort of HIV-positive adults all the way
from testing to treatment initiation if they were not already
eligible for ART when diagnosed. While in retrospect this points
to a failure of the research community to establish prospective
cohorts several years ago, it also reflects the sheer difficulty posed
by such research. In most settings we are familiar with, it is
virtually impossible to determine retrospectively what happens to
patients after testing positive for HIV, as there is no tracking
system in place to indicate whether they have sought further care
or not. In our experience, even where sophisticated electronic
record systems are in use for managing ART patients, they are
rarely kept up to date or complete for those who have not
initiated ART.
Figure 5. Forest plot of the 14 studies reporting on the proportion of patients completing Stage 3 or steps within Stage 3. Bars
indicate 95% confidence intervals. Studies shown in the plot report to differing end points; refer to Table 4 for details.
doi:10.1371/journal.pmed.1001056.g005
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problem of pre-ART loss to care might thus be to implement
effective patient tracking systems in selected geographic
catchment areas that will generate accurate information on
attrition between and within stag e sa n dh e l pr e s e a r c h e r sa s s e s s
the role of patient mobility in offsetting observed attrition,
identify characteristics of patients most likely to be lost, and
explore the extent to which attrition from pre-ART care is
temporary—i.e., delay in action by patients who will later return
to care, albeit sicker—or represents permanent loss from the
health-care system, which will likely ultimately lead to death.
Even doing this on a relatively small scale will be challenging, as
it has been for ART patients [15], but it is a vital intervention
for improving pre-ART care.
Table 5. Proportions of patients retained between stages of pre-ART care.
Study Code
Stages and Start and End
Points Study Outcome N
Number Achieving
Outcome
Percent Achieving
Outcome Comments
Malawi 2 Stages 1–3. HIV testing to
staging, retention in pre-ART
care, and ART eligibility to ART
initiation
Proportions of patients in
WHO stage 1 or 2 and CD4
.250 cells/mm
3 at
enrollment who enrolled
in HIV care, provided sample
for CD4 count, and initiated
ART by date of data
censoring
1,633 808 49% 95% of losses to follow-up
occurred in Stage 1; does
not report stage
completion for patients
still in pre-ART care at data
censoring
SA 6 Stages 1–3. HIV testing to
staging, retention in pre-ART
care, and ART eligibility to ART
initiation
Proportion who initiated ART
or had a repeat CD4 count
by date of data censoring
988 330 33% Does not report stage
completion for patients
not eligible for ART upon
receipt of first CD4 count
results
SA 4 Stages 2 and 3. Staging to ART
initiation or data censoring
Proportion of those enrolled
in program and with CD4
count reported who initiated
ART or remained in care at
date of data censoring
33,122 18,851 57% Does not report stage
completion for patients
not eligible for ART upon
receipt of first CD4 count
results
SA 14 Stages 1 and 2. HIV testing to
staging, and staging to
enrollment in care
Proportion who returned for
CD4 count results
192 149 77% Does not report time limit
for completing steps
Proportion of those who
returned for CD4 count
results who reported
accessing HIV care
135 49 36%
Mozambique 1 Stages 1 and 3. HIV testing to
staging, and ART eligibility to
ART initiation
Proportion who returned
for CD4 count results #60
d of HIV test
6,999 3,046 44% Does not report outcomes
for patients not eligible for
ART upon receipt of CD4
count results
Proportion of those ART-
eligible at first CD4 count
who initiated ART #90 d
of CD4 count
1,506 417 31%
SA 1 Stages 1 and 3. HIV testing to
staging, and ART eligibility to
ART initiation
Proportion who had C4
count #6m o
375 233 62% Does not report outcomes
for patients not eligible for
ART upon receipt of CD4
count results
Proportion of those ART-
eligible at first CD4 count
who initiated ART #6m o
of HIV test
75 51 68%
SA 3 Stages 1 and 3. HIV testing to
staging, and ART eligibility to
ART initiation
Proportion who returned for
CD4 count results #90 d
of HIV test
1,474 1,012 69% Does not report outcomes
for patients not eligible for
ART upon receipt of CD4
count results
Proportion of those ART-
eligible at first CD4 count
who initiated ART #12 mo
of CD4 count
538 210 39%
Uganda 1 Stages 1 and 3. HIV testing to
staging, and ART eligibility to
ART initiation
Of those who provided
samples for CD4 count
and were ART-eligible,
proportion initiating ART
vwithin an unspecified
time period (,1y )
2,483 1,846 74% Excluded patients not yet
ART-eligible at time of first
CD4 count
doi:10.1371/journal.pmed.1001056.t005
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The heterogeneity of the literatureidentified, and the sheer scarcity
of studies found for most sub-Saharan countries, led to a number of
review limitations that are important to bear in mind in interpreting
our findings. Most of these limitations have been alluded to already
but warrant reiteration here. First, the quality and heterogeneity of
the studies prevented meaningful synthesis of the results, which
should therefore be regarded as suggestive rather than conclusive.
The lack of standard definitions among reports, or even clear
definitions of outcome measures within some (but not all) of the
reports, combined with inconsistent or unreported durations of
follow-up, stymied aggregate analysis. This limitation should be kept
in mind in interpreting the forest plots and the summary figure
(Figure6)inparticular.Second,double-countinglikelyaffectssomeof
the studies. Patients who are lost from one stage of care can return to
care later and either successfully complete the stage or be lost again.
Single-stage studies can tell us whether patients remain continuously
in care until the end of the stage but should not be combined with
studies of other stages, as demonstrated by our multiplying of median
estimates above. Third, thereis likely important heterogeneity among
study populations that could not be discerned from most reports. For
example, patients who enroll in pre-ART care (Stage 2) with low
CD4 counts, close to the ART eligibility threshold, have less time at
risk of being lost from care than those who enroll earlier, with higher
CD4 counts, but few studies reported this information. Fourth, half of
the studies eligible for inclusion in our review came from just one
country, South Africa, and onlysix other countries arerepresented by
the rest of the studies. This may diminish the generalizability of the
findings to the sub-Saharan region as a whole. Fifth, eight of the 28
studies included were in abstract form only and were thus not
subjected to peer review. Finally, publication bias may have affected
our summary estimates. Only a few HIV clinics in sub-Saharan
Africa have published information about pre-ART loss to care, and
most of these sites collaborate with nongovernmental organizations,
universities, or other external partners. If sites that have the ability
and resources to report on such data haveeither lower or higher than
average retention rates, our summary estimates will be biased.
Needless to say, new health information systems or studies
launched now—the best solution to the problems described
above—will require several years to accumulate the duration of
follow-up needed. We therefore conclude with a call to HIV/
AIDS service delivery organizations in the field. We think it likely
that some programs have captured the data needed to analyze pre-
ART loss to care through all three stages. We speculate that in
Figure 6. Summary of proportions of patients completing steps within each stage of pre-ART care in the studies reviewed.
doi:10.1371/journal.pmed.1001056.g006
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every step of HIV care and treatment delivery. If that organization
has also assigned a unique patient identification number to all
those served, beginning with HIV testing, then an adequate data
set may exist. We hope that this paper will inspire those who may
have such data to try to answer the questions raised here, and that
we will soon begin to see the results of this effort in the literature.
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Background. Since 1981, AIDS has killed more than 25
million people, and about 33 million people (mostly living in
low- and middle-income countries) are now infected with
HIV, the virus that causes AIDS. HIV gradually destroys
immune system cells (including CD4 cells, a type of
lymphocyte), leaving infected individuals susceptible to
other infections. Early in the AIDS epidemic, most HIV-
infected people died within ten years of infection. Then, in
1996, highly active antiretroviral therapy (ART) became
available, and, for people living in developed countries, HIV
infection became a chronic condition. Unfortunately, ART
was extremely expensive, and HIV/AIDS remained a fatal
illness for people living in developing countries. In 2003,
governments, international agencies, and funding bodies
began to implement plans to increase ART coverage in
resource-limited countries. By the end of 2009, about a third
of the people in these countries who needed ART (HIV-
positive people whose CD4 count had dropped so low that
they could not fight other infections) were receiving
treatment.
Why Was This Study Done? Unfortunately, many HIV-
positive people in resource-limited countries who receive
ART still do not have a normal life expectancy, often because
they start ART when they have a very low CD4 count. ART is
more successful if it is started before the CD4 count falls far
below 350 cells/mm
3 of blood, the threshold recommended
by the World Health Organization for ART initiation. Thus, if
the outcomes of HIV/AIDS programs in resource-limited
settings are to be improved, all individuals testing positive
for HIV must receive continuous pre-ART care that includes
regular CD4 counts to ensure that ART is initiated as soon as
they become eligible for treatment. Before interventions can
be developed to achieve this aim, it is necessary to
understand where and when patients are lost to pre-ART
care. In this systematic review (a study that uses predefined
criteria to identify all the research on a given topic), the
researchers investigate the retention of HIV-positive adults in
pre-ART care in sub-Saharan Africa.
What Did the Researchers Do and Find? The researchers
identified 28 studies that included data on the proportion of
adult patients retained between any two time points
between testing positive for HIV and starting ART in HIV/
AIDS care programs in sub-Saharan Africa. They defined
three stages of pre-ART care: Stage 1, the interval between
testing positive for HIV and receiving CD4 count results or
being clinically assessed; Stage 2, the interval between
enrollment in pre-ART care and the determination of
eligibility for ART; and Stage 3, the interval between being
deemed eligible for ART and treatment initiation. A median
of 59% of patients were retained in Stage 1 of pre-ART care,
46% were retained in Stage 2, and 68% were retained in
Stage 3. Retention rates in each stage differed greatly
between studies—between 14% and 84% for Stage 3 pre-
ART care, for example. Because the enrollment criteria and
other characteristics of the identified studies varied widely
and were often poorly defined, it was hard to combine study
results. Nevertheless, the researchers estimate that, taking all
the studies together, less than one-third of patients testing
positive for HIV but not eligible for ART when diagnosed
were retained in pre-ART care continuously.
What Do These Findings Mean? These findings suggest
that there is a substantial loss of HIV-positive patients at
every stage of pre-ART care in sub-Saharan Africa. Thus,
some patients receiving a positive HIV test never return for
the results of their initial CD4 count, some disappear
between having an initial CD4 count and becoming
eligible for ART, and others fail to initiate ART after having
been found eligible for treatment. Because only a few studies
were identified (half of which were undertaken in South
Africa) and because the quality and design of some of these
studies were suboptimal, the findings of this systematic
review must be treated with caution. In particular, the
estimate of the overall loss of patients during pre-ART care is
likely to be imprecise. The researchers call, therefore, for the
implementation of better health information systems that
would allow patients to be tracked between service delivery
points as a way to improve the evaluation and
understanding of the loss of HIV-positive patients to pre-
ART care in resource-limited countries.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001056.
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS
N HIV InSite has comprehensive information on all aspects of
HIV/AIDS
N Information is available from Avert, an international AIDS
charity on many aspects of HIV/AIDS, including informa-
tion on HIV/AIDS treatment and care, on HIV and AIDS in
Africa and on universal access to AIDS treatment (in
English and Spanish)
N The World Health Organization provides information about
universal access to AIDS treatment, including the 2010
progress report (in English, French and Spanish); its 2010
ART guidelines can be downloaded (in several languages)
N The International AIDS Economics Network posts informa-
tion about economic, social, and behavioral aspects of HIV
care and treatment
N Up-to-date research findings about HIV care and treatment
are summarized by NAM/aidsmap
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